Kristie L. Kahl

Articles

Study confirms adding palbociclib to endocrine therapy may not improve outcomes in early breast cancer

December 10, 2021

The addition of palbociclib to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.